TY - JOUR T1 - Practical Considerations for Implementation of <sup>177</sup>Lu-DOTATATE Neuroendocrine Tumor Treatment Programs JF - Journal of Nuclear Medicine Technology JO - J. Nucl. Med. Technol. SP - 195 LP - 202 DO - 10.2967/jnmt.122.263813 VL - 50 IS - 3 AU - Diane K. Soulek AU - Molly E. Martin AU - Nic J. Mastascusa AU - Stephen A. Graves Y1 - 2022/09/01 UR - http://tech.snmjournals.org/content/50/3/195.abstract N2 - The 2018 Food and Drug Administration approval of 177Lu-DOTATATE for the treatment of somatostatin receptor–positive neuroendocrine tumors (NETs) represents a paradigm-shifting approach to cancer treatments around the globe. Gastroenteropancreatic NETs overexpress the somatostatin subtype receptor 2, which is now exploited for receptor-based imaging and therapy, thus generating significant progress in the diagnosis and treatment of this orphan disease. The recent Food and Drug Administration approval of receptor-based PET radiopharmaceuticals and a new peptide receptor radiopharmaceutical therapy, 177Lu-DOTATATE, has dramatically impacted NET patient management. The focus of this paper is to review clinical considerations associated with implementing a 177Lu-DOTATATE program. We review receptor-based NET radiopharmaceuticals; 177Lu-DOTATATE patient selection criteria; administration methods; clinical, regulatory, and radiation safety considerations; technical factors; tissue dosimetry; and reimbursement guidelines. ER -